Share on StockTwits

Bioamber (NASDAQ:BIOA) Director Kurt W. Briner acquired 14,250 shares of the stock on the open market in a transaction dated Monday, August 25th. The stock was purchased at an average price of $11.50 per share, with a total value of $163,875.00. Following the completion of the transaction, the director now directly owns 50,630 shares of the company’s stock, valued at approximately $582,245. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Bioamber (NASDAQ:BIOA) traded up 0.40% during mid-day trading on Tuesday, hitting $11.9978. 10,061 shares of the company’s stock traded hands. Bioamber has a 52-week low of $3.96 and a 52-week high of $15.29. The stock’s 50-day moving average is $12.02 and its 200-day moving average is $11.52. The company’s market cap is $261.6 million.

Bioamber (NASDAQ:BIOA) last announced its earnings results on Thursday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.04. On average, analysts predict that Bioamber will post $-1.78 earnings per share for the current fiscal year.

BIOA has been the subject of a number of recent research reports. Analysts at Societe Generale raised their price target on shares of Bioamber to $16.00 in a research note on Friday, July 18th. Separately, analysts at Barclays cut their price target on shares of Bioamber from $22.00 to $20.00 in a research note on Thursday, July 17th. Finally, analysts at Barclays raised their price target on shares of Bioamber from $13.00 to $22.00 in a research note on Thursday, July 10th. They now have an “overweight” rating on the stock.

BioAmber Inc (NASDAQ:BIOA) is a chemical company.

Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.